Journal
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
Volume 19, Issue 9, Pages 1006-1019Publisher
HARBORSIDE PRESS
DOI: 10.6004/jnccn.2021.0043
Keywords
-
Categories
Funding
- Agios Pharmaceuticals
- AstraZeneca
- Clovis Oncology, Inc.
- Daiichi Sankyo
- Eisai
- Epizyme Inc.
- Novartis
- Pharmacyclics LLC
- AbbVie Company
- Janssen Biotech, Inc.
- Bristol-Myers Squibb
- Regeneron Pharmaceuticals, Inc.
- Sanofi Genzyme
- Mylan Inc.
- Karyopharm Therapeutics
- AbbVie
Ask authors/readers for more resources
The NCCN Guidelines for Older Adult Oncology address specific issues related to cancer management in older adults, with a focus on comprehensive geriatric assessment (CGA) as a multidisciplinary evaluation method to assess health status and various domains relevant to cancer treatment choices. Recent updates to the guidelines provide a specific practical framework for using CGA in evaluating older adults with cancer.
The NCCN Guidelines for Older Adult Oncology address specific issues related to the management of cancer in older adults, including screening and comprehensive geriatric assessment (CGA), assessing the risks and benefits of treatment, preventing or decreasing complications from therapy, and managing patients deemed to be at high risk for treatment-related toxicity. CGA is a multidisciplinary, in-depth evaluation that assesses the objective health of the older adult while evaluating multiple domains, which may affect cancer prognosis and treatment choices. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines providing specific practical framework for the use of CGA when evaluating older adults with cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available